Scholarlink

<p>According to the World Health Organization (WHO) obesity is classified as a&#xa0;chronic relapsing disease with a&#xa0;multifactorial etiology and is closely associated with a&#xa0;range of metabolic and cardiovascular comorbidities, including type&#xa0;2 diabetes mellitus, arterial hypertension and metabolic dysfunction-associated steatotic liver disease (MASLD). Since the 1970s the global prevalence of obesity has more than tripled and currently affects approximately two thirds of adults in Europe. The body mass index (BMI) alone is no longer considered sufficient for individual risk stratification and the waist-to-height ratio (&gt; 0.5) has emerged as a&#xa0;more predictive marker for visceral obesity and associated metabolic risk. The MASLD and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are increasingly recognized as independent cardiovascular risk factors reflecting a&#xa0;state of systemic metabolic dysregulation. Contributing pathophysiological mechanisms include endothelial dysfunction, subclinical chronic inflammation, atherogenic dyslipidemia and insulin resistance. As part of a&#xa0;therapeutic approach, a&#xa0;weight loss of around 10% or more of the initial body weight is recommended to improve hepatic inflammation and fibrosis. A&#xa0;fiber-rich low-sugar diet, consistent with the principles of the Mediterranean dietary pattern, combined with a&#xa0;daily protein intake of 1.0–1.2 g/kg body weight and, if necessary, supported by protein-based formula diets, has been shown to reduce hepatic fat content, improve insulin sensitivity and decrease systemic inflammatory markers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Allgemeine Ernährungsempfehlungen bei Adipositas und Fettleber

  • 期刊论文

  • 发表日期：

    2025年11月3日

查看全文
  • Elena Müller-Moré

摘要

According to the World Health Organization (WHO) obesity is classified as a chronic relapsing disease with a multifactorial etiology and is closely associated with a range of metabolic and cardiovascular comorbidities, including type 2 diabetes mellitus, arterial hypertension and metabolic dysfunction-associated steatotic liver disease (MASLD). Since the 1970s the global prevalence of obesity has more than tripled and currently affects approximately two thirds of adults in Europe. The body mass index (BMI) alone is no longer considered sufficient for individual risk stratification and the waist-to-height ratio (> 0.5) has emerged as a more predictive marker for visceral obesity and associated metabolic risk. The MASLD and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are increasingly recognized as independent cardiovascular risk factors reflecting a state of systemic metabolic dysregulation. Contributing pathophysiological mechanisms include endothelial dysfunction, subclinical chronic inflammation, atherogenic dyslipidemia and insulin resistance. As part of a therapeutic approach, a weight loss of around 10% or more of the initial body weight is recommended to improve hepatic inflammation and fibrosis. A fiber-rich low-sugar diet, consistent with the principles of the Mediterranean dietary pattern, combined with a daily protein intake of 1.0–1.2 g/kg body weight and, if necessary, supported by protein-based formula diets, has been shown to reduce hepatic fat content, improve insulin sensitivity and decrease systemic inflammatory markers.